Can a smart drug home in on Hard-to-Treat cancers?

This trial is testing an experimental drug called XNW27011 in people with advanced solid tumors, such as pancreatic, lung, ovarian, colorectal, biliary tract, stomach, or gastroesophageal junction cancer, that have not responded to or are not eligible for standard treatments. XNW27011 is a type of targeted therapy called an antibody-drug conjugate, designed to seek out and deliver a toxic payload to cancer cells that carry a specific protein called Claudin 18.2. The study has two parts: the first part finds the safest dose, and the second part checks how well that dose shrinks tumors in patients whose tumors express this protein.